Respiratory Events and Procedure Interruptions During Pediatric Bronchoscopy and Suspension Laryngoscopy: A Secondary Analysis Comparing Dexmedetomidine and Remifentanil‐Based Anesthesia Authors: Clyde T. Matava, Brenda Nkonge, Martina Bordini, Julia M. Olsen, Jennifer M. Siu, Jason Macartney, Nikolaus E. Wolter, Evan J. Propst Published: 2026 Pediatric rigid bronchoscopy and suspension laryngoscopy demand anesthetic techniques that maintain sedation while preserving spontaneous ventilation. Clinicians often combine propofol with either remifentanil or dexmedetomidine, but direct comparisons of respiratory safety are rare. We analyzed data from a prospective observational study to evaluate how these regimens influence respiratory events and procedural stability [1, 2]. The Hospital for Sick Children Research Ethics Board approved the parent study (REB #1000080874). Between September 2023 and March 2024, we enrolled 30 children aged 1–12 years undergoing rigid bronchoscopy or suspension laryngoscopy [3]. All procedures used spontaneous ventilation and transcutaneous carbon dioxide (TcCO2) monitoring. The parent study found that all patients developed intraoperative hypercapnia (TcCO2 > 50 mmHg for ≥ 1 min), and 60% experienced hypercapnia in the post‐anesthesia care unit (PACU), with five children reaching severe hypercapnia (> 70 mmHg). We grouped patients according to anesthetic regimen: Dex (propofol + dexmedetomidine), Remi (propofol + remifentanil), Remi+Dex High (propofol + remifentanil + ≥ 0.6 μg/kg dexmedetomidine), and Remi+Dex Low (< 0.6 μg/kg dexmedetomidine). The anesthesia team maintained spontaneous ventilation in all cases. Research staff prospectively recorded apnea (≥ 30 s without breathing), cough, and need for bag‐mask ventilation (BMV). They also documented any procedure interruptions caused by airway or anesthetic instability. We assessed time to awakening and PACU length of stay as recovery outcomes. Demographic and procedural characteristics were similar across groups (Table S1). Most children were ASA II–III with comparable rates of obstructive sleep apnea and congenital airway anomalies. The characteristics of the anesthesia regimens are outlined in Table S2. Dexmedetomidine‐only anesthesia produced the most stable respiratory profile. None of these children (n = 3) coughed, developed apnea, or required BMV (Table 1). In contrast, regimens containing remifentanil—alone or with dexmedetomidine—led to more apnea and BMV events, especially during induction and bronchoscope insertion or removal. Cough appeared only with remifentanil‐containing regimens. The anesthesia team interrupted surgery most often in the combination groups (three interruptions each) and twice in the Remi group, compared with none in the Dex group. TABLE 1Summary of key outcomes by anesthetic group.DexRemi+Dex HighRemi+Dex LowRemi n 312510Apnea/BMV events0532Cough0YesYesYesProcedure interruptions0332Median awakening time (min, IQR)109.5 [93.8–125.3]76.0 [56.0–98.8]61.0 [39.0–80.0]44.5 [35.0–59.5]PACU stay (mean ± SD, min)119.0 ± 35.497.3 ± 29.467.8 ± 20.593.1 ± 32.7 Summary of key outcomes by anesthetic group. Recovery profiles showed the opposite pattern. Children receiving Dex took longest to awaken (median 109.5 min [IQR 93.8–125.3]) and to discharge from PACU (119.0 ± 35.4 min). Those in the Remi group recovered fastest (median awakening 44.5 min [35.0–59.5]) and left PACU sooner. The Remi+Dex Low group also demonstrated short PACU stays (67.8 ± 20.5 min). These data illustrate a clear trade‐off: dexmedetomidine improved respiratory stability but delayed recovery, while remifentanil accelerated emergence but increased airway instability. Patients undergoing interventional procedure were more likely to receive a remifentanil‐based anesthetic. These results align with expected pharmacologic differences. Dexmedetomidine provides sedation and analgesia without significant respiratory depression, explaining the absence of apnea or BMV. However, its slower offset prolongs emergence. Remifentanil's rapid metabolism enables quick titration and recovery but can produce dose‐dependent respiratory depression and cough when used with spontaneous ventilation. Higher dexmedetomidine doses in combination with remifentanil appeared to worsen respiratory instability, suggesting possible additive effects. Clinicians using such combinations should anticipate and prepare for airway intervention. Despite these risks, remifentanil's predictable pharmacokinetics make it appealing in high‐throughput airway programs. Using high‐flow nasal oxygen may reduce desaturation and minimize surgical interruptions [4, 5]. Dexmedetomidine's longer recovery times could impact workflow efficiency. A 60‐min recovery difference can alter daily case scheduling in pediatric operating rooms. However, in children with complex airways, severe obstruction, or contraindications to opioids, dexmedetomidine may remain the preferred choice for maintaining ventilation safety. Based on this analysis, a future randomized comparison of dexmedetomidine and remifentanil would require roughly 45 patients per group to detect a twofold difference in apnea incidence with 80% power and α = 0.05. Although our sample was small and the study observational, these findings highlight clinically important trade‐offs and inform the design of future trials. We now plan a multicenter platform trial to evaluate these anesthetic regimens concurrently using a shared control arm. This adaptive design will allow efficient enrollment, shared baseline characterization, and dynamic incorporation of new interventions over time. In summary, dexmedetomidine‐based anesthesia minimized respiratory events and eliminated intraoperative interruptions but prolonged recovery. Remifentanil‐based regimens shortened recovery but increased airway instability. Clinicians must balance respiratory safety against efficiency when selecting anesthetic techniques for shared airway surgery. A future adaptive platform trial will provide the statistical power and flexibility needed to establish evidence‐based regimens for pediatric airway management. Author Contributions Clyde T. Matava: conceived the study, designed the study, implemented the study protocol, and wrote and edited the manuscript. Brenda Nkonge: performed statistical analysis and wrote and edited the manuscript. Martina Bordini: designed the study, implemented the study protocol, completed data collection, performed statistical analysis, and wrote and edited the manuscript. Julia M. Olsen, Jennifer M. Siu, Jason Macartney, Nikolaus E. Wolter, and Evan J. Propst: implemented the study protocol and wrote and edited the manuscript. Funding The authors have nothing to report. Ethics Statement This study was approved by the research ethics board at The Hospital for Sick Children, Toronto, Canada (REB##1000080874). Written informed consent was obtained from the parent/guardian or from the patient for all participants. Conflicts of Interest C.T.M. is a Section Editor at Pediatric Anesthesia. None of the other authors declare no conflicts of interest. Supporting information Table S1: Demographics of the patients. Table S2: Anesthesia regimens.